0000950170-23-063926.txt : 20231114
0000950170-23-063926.hdr.sgml : 20231114
20231114192253
ACCESSION NUMBER: 0000950170-23-063926
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231110
FILED AS OF DATE: 20231114
DATE AS OF CHANGE: 20231114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JENSEN MICHAEL VANGSTED
CENTRAL INDEX KEY: 0001914184
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37566
FILM NUMBER: 231408621
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET, SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNLOGIC, INC.
CENTRAL INDEX KEY: 0001527599
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261824804
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-401-9975
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Mirna Therapeutics, Inc.
DATE OF NAME CHANGE: 20110809
4
1
ownership.xml
4
X0508
4
2023-11-10
0001527599
SYNLOGIC, INC.
SYBX
0001914184
JENSEN MICHAEL VANGSTED
C/O SYNLOGIC, INC.
301 BINNEY STREET, SUITE 402
CAMBRIDGE
MA
02142
true
Chief Financial Officer
false
Stock Option (right to buy)
33.45
2023-11-10
4
D
false
15332
D
2032-03-03
Common Stock
15332
0
D
Stock Option (right to buy)
9.30
2023-11-10
4
D
false
13332
D
2033-03-16
Common Stock
13332
0
D
Stock Option (right to buy)
9.30
2023-11-10
4
D
false
6666
D
2033-03-16
Common Stock
6666
0
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
15332
A
2032-03-03
Common Stock
15332
15332
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
13332
A
2033-03-16
Common Stock
13332
13332
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
6666
A
2033-03-16
Common Stock
6666
6666
D
In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
These stock options vested 25% on the first anniversary of the March 3, 2022 grant date, and vest in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.
/s/ Michael Vangsted Jensen
2023-11-14